Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
series C
Biotech
Terremoto takes $108M series C to fuel trials of AKT1 inhibitors
Terremoto has spelt out how the California biotech will use a $108 million round to continue its efforts to broaden the covalent drug alphabet.
James Waldron
Apr 15, 2026 7:43am
Endogenex nets $50M to develop pulsed-field diabetes procedure
Mar 25, 2026 10:48am
Cognito reaps $105M in funding for its Alzheimer's device
Mar 6, 2026 7:30am
Science closes major $230M series C round
Mar 5, 2026 10:50am
Soley secures $200M series C to take cell stress drug to clinic
Jan 7, 2026 8:55am
Fierce Biotech Fundraising Tracker: Syneron, Atavistik & more
Dec 19, 2025 2:00pm
